Greater China Strategy | Alpha Picks: February Conviction Calls Chinese equities recovered in January, with the HSI and MSCI China rising 6.9% and 5.0% mom respectively. Given the supportive macro policy environment, we maintain a constructive view on the markets despite the risk of further volatility in February. Accordingly, we are adding Alibaba, Ganfeng Lithium, and Minth to our BUY list, and Meituan to our SELL list. Indonesia Strategy | Alpha Picks: From MSCI Shock To Policy-Driven Rebala...
Greater China Sector Update | China Property CRIC data show that the top 100 developers’ contracted sales fell 24.7% yoy in Jan 26, while new-home sales in 28 major cities declined 36% yoy. Second-hand transactions in three Tier 1 cities rose 1% yoy. Maintain UNDERWEIGHT but deepening industry downturn leads to rising possibility of policy support, supporting selective exposure. CR Land remains our top pick, with P/B at 1SD below the five-year mean, and PE and yield near the five-year average....
Greater China Company Update | NAURA Technology Group (002371 CH/BUY/Rmb497.68/Target: Rmb571.70) We see multiple upside risks to our assumption about NAURA for 2026-27. Domestic foundries and memory IDMs are likely to further raise their capex plans for advanced nodes given robust downstream demand and capacity shortage, while the mature node capex may end up better than feared thanks to overflow demand from global Tier 1 foundries. On the other hand, localisation efforts are accelerating signi...
Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.00/Target: Bt32.00) BDMS is expected to report a substantial earnings contraction in 4Q25, with net profit forecast at Bt3.81b (-12.1% yoy, -11.8% qoq), pressured by flood-related costs, higher provisions, and rising expenses, despite moderate revenue growth on a strong epidemic-driven Thai patient base. Margins are projected to fall materially. While near-term earnings face headwinds, the epidemic remains a key support, copayment...
Top Stories Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.00/Target: Bt32.00) BDMS is expected to report a substantial earnings contraction in 4Q25, with net profit forecast at Bt3.81b (-12.1% yoy, -11.8% qoq), pressured by flood-related costs, higher provisions, and rising expenses, despite moderate revenue growth on a strong epidemic-driven Thai patient base. Margins are projected to fall materially. While near-term earnings face headwinds, the epidemic remains a key supp...
A director at Bangkok Dusit Medical Services Public Company Limited bought 1,668,500 shares at 18.400THB and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
Greater China Strategy | Alpha Picks: January Conviction Calls Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December pic...
Greater China Strategy | Alpha Picks: January Conviction Calls Chinese equities remained in consolidation through December, with the HSI and MSCI China down 0.9% mom and 1.5% mom, respectively, despite last week’s window dressing narrowing losses. Policy signals from the Economic Work Conference broadly met expectations. Looking ahead, we are constructive on 1Q26, supported by a favourable global liquidity cycle and potential macro supportive measures in China. We retain most of our December...
Greater China Sector Update | China Property Demand stayed weak in Nov 25, with new-home sales in 28 cities down 42% yoy and second hand home prices in most cities falling. Land auctions in Shanghai and Hangzhou cooled, with most plots near reserve prices. We maintain UNDERWEIGHT on China property, with CR Land as our top pick for its consistent earnings outperformance. Sector Update | Macau Gaming Macau’s Nov 25 GGR reached MOP 21.1b, down 12% mom but up 14% yoy, and recovering to 92% o...
Greater China Economics | Money Supply M1 growth fell to 6.2% yoy in October, short of expectations, while M2 growth eased to 8.2% yoy. New bank loans dropped sharply to Rmb0.22t, and new TSF fell to Rmb0.81t, both below forecasts. Outstanding TSF and bank loan growth moderated to 8.5% (-0.2ppt mom) and 6.5% yoy (-0.1ppt mom) respectively, with the decline led by household loans. The numbers are not encouraging. Sector Update | Automobile China’s PV retail sales basically remained flat yoy in O...
Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt19.70/Target: Bt32.00) The tone at BDMS’ analyst meeting tone was positive, with management maintaining a strong outlook for 4Q25 supported by the ongoing influenza outbreak. Influenza cases surged 44.9% yoy in Week 45, boosting Thai patient revenue by 8% yoy in Oct 25. 3Q25 net profit came in at Bt4.3b (+1.7% yoy), beating consensus by 5%. While the Ministry of Commerce’s new measure may slightly affect top-line, BDMS plans to mitig...
Top Stories Company Results | AP (Thailand) (AP TB/BUY/Bt7.90/Target: Bt9.30) AP posted a net profit of Bt1.15b in 3Q25 (-20% yoy, +15% qoq), in line with our estimate. The qoq improvement was underpinned by a solid performance in the low-rise segment, improved gross margin and higher equity income. AP revised down its 2025 launch plan from Bt65.0b to Bt59.6b. However, we are optimistic about the presales and earnings outlook for 4Q25. We still like AP as the market leader with a more aggressi...
Company Update | Bangkok Dusit Medical Services (BDMS TB/BUY/Bt20.20/Target: Bt32.00) BDMS is expected to post 3Q25 net profit of Bt4.19b (-1.2% yoy, +20.2% qoq), with mild topline growth to Bt28.5b, supported by strong epidemic-related cases in Sep 25 but offset by a high base last year and weaker Cambodian revenue. The ongoing flu outbreak, up 18.3% yoy, should extend benefits into 4Q25, boosting Thai patient volume. The new Ministry of Commerce measure should have minimal (
Top Stories Sector Update | Electronics We expect the combined 3Q25 core profit of Thai electronic stocks under our coverage to decline 13% yoy, pressured by lower gross margins from baht appreciation, but to increase 18% qoq, supported by higher revenue and margin improvement. We upgrade the sector to MARKET WEIGHT with KCE as our top pick, as geopolitical uncertainty has eased; however, we expect the recovery to be gradual, as the sector will likely remain under pressure from the strong bah...
Greater China Sector Update | Property Jinling Residence’s strong sell-out highlights resilient end-user demand despite weaker investment sentiment, while major cities’ October data showed yoy declines in both new and secondary home sales. We maintain MARKET WEIGHT. We upgrade Kerry Properties to BUY after the recent correction, with an unchanged target price of HK$22.80. Company Update | Alibaba Group (9988 HK/BUY/HK$155.20/Target: HK$203.00) We expect solid 2QFY26 results, despite marg...
Greater China Sector Update | Automobile China’s PV sales rebounded last week, with PEV growth surging from below 5% to over 30% due to subsidies and new models. Geely and XPeng led, while BYD and Li Auto lagged. Vehicle exports rose 26% yoy in August, driven by gains in the EU, Africa, and Middle East. Maintain MARKET WEIGHT. Top BUYs: CATL (target price raised to Rmb520) and Geely. Top SELLs: BYD and Li Auto. Sector Update | Healthcare Falling interest rates are expected to significant...
The tone at BDMS’ 2Q25 analyst meeting was neutral. Management revised down its 2025 revenue growth target further to 3-5% yoy to reflect the current ongoing conflict between Thailand and Cambodia. The outlook in 3Q25 is quite challenging as Jul 25 was not a good month for BDMS. Last year’s earnings base was high from the epidemic, and the conflict has yet to die down. However, we still prefer BDMS as a long-term pick. Maintain BUY. Target price: Bt32.00.
KEY HIGHLIGHTS Results COM7 (COM7 TB/BUY/Bt24.50/Target: Bt29.50) 2Q25: Better-than-expected earnings. Electricity Generating (EGCO TB/BUY/Bt113.00/Target: Bt125.00) 2Q25: Results beat expectations, with yield remaining impressive. GFPT (GFPT TB/BUY/Bt10.10/Target: Bt15.50) 2Q25: Earnings beat expectations on solid profitability. Hana Microelectronics (HANA TB/HOLD/Bt22.60/Target: Bt20.00) ...
GREATER CHINA Sector Automobile Weekly: Yoy growth of China’s PEV sales turns negative; lithium price recovers. Maintain MARKET WEIGHT on the sector. Top BUYs: CATL, Geely and Tuopu. Results Geely Auto (175 HK/BUY/HK$18.95/Target: HK$42.00) 2Q25: Core earnings surge 93% yoy, in line; raise target price to HK$42.00. Maintain BUY. Hysan Development (14 HK/BUY/HK$15.67/Target: HK$17.84) ...
BDMS reported a net profit of Bt3.5b in 2Q25 (+4.6% yoy, -19.7% qoq) which is in line with our forecast and the consensus. The top-line came in at Bt26.7b (+4.0% yoy, -4.8% qoq), with main contributions from a mild revenue growth from Thai patients of 3% yoy and strong revenue growth from international patients of 6% yoy. The strong growth from key nations were able to offset a slowdown from the latest Thai-Cambodia conflict. Maintain BUY. Target price: Bt32.00.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.